Tiziana Life Sciences (TLSA) Competitors $1.23 +0.15 (+13.89%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$1.23 0.00 (-0.41%) As of 03/25/2025 07:28 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock TLSA vs. DNTH, LENZ, CRMD, SION, ORGO, ABUS, SANA, CDXC, KALV, and MGTXShould you be buying Tiziana Life Sciences stock or one of its competitors? The main competitors of Tiziana Life Sciences include Dianthus Therapeutics (DNTH), LENZ Therapeutics (LENZ), CorMedix (CRMD), Sionna Therapeutics (SION), Organogenesis (ORGO), Arbutus Biopharma (ABUS), Sana Biotechnology (SANA), ChromaDex (CDXC), KalVista Pharmaceuticals (KALV), and MeiraGTx (MGTX). These companies are all part of the "pharmaceutical products" industry. Tiziana Life Sciences vs. Dianthus Therapeutics LENZ Therapeutics CorMedix Sionna Therapeutics Organogenesis Arbutus Biopharma Sana Biotechnology ChromaDex KalVista Pharmaceuticals MeiraGTx Dianthus Therapeutics (NASDAQ:DNTH) and Tiziana Life Sciences (NASDAQ:TLSA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, community ranking, institutional ownership, risk, profitability and valuation. Does the media prefer DNTH or TLSA? In the previous week, Tiziana Life Sciences had 2 more articles in the media than Dianthus Therapeutics. MarketBeat recorded 3 mentions for Tiziana Life Sciences and 1 mentions for Dianthus Therapeutics. Tiziana Life Sciences' average media sentiment score of 0.96 beat Dianthus Therapeutics' score of 0.73 indicating that Tiziana Life Sciences is being referred to more favorably in the news media. Company Overall Sentiment Dianthus Therapeutics Positive Tiziana Life Sciences Positive Do analysts rate DNTH or TLSA? Dianthus Therapeutics currently has a consensus price target of $54.33, indicating a potential upside of 197.07%. Given Dianthus Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Dianthus Therapeutics is more favorable than Tiziana Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22Tiziana Life Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better valuation & earnings, DNTH or TLSA? Tiziana Life Sciences has lower revenue, but higher earnings than Dianthus Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDianthus Therapeutics$6.24M94.24-$43.56M-$2.60-7.03Tiziana Life SciencesN/AN/A-$17.69MN/AN/A Does the MarketBeat Community favor DNTH or TLSA? Tiziana Life Sciences received 70 more outperform votes than Dianthus Therapeutics when rated by MarketBeat users. However, 96.30% of users gave Dianthus Therapeutics an outperform vote while only 63.58% of users gave Tiziana Life Sciences an outperform vote. CompanyUnderperformOutperformDianthus TherapeuticsOutperform Votes2696.30% Underperform Votes13.70%Tiziana Life SciencesOutperform Votes9663.58% Underperform Votes5536.42% Which has more volatility and risk, DNTH or TLSA? Dianthus Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the S&P 500. Comparatively, Tiziana Life Sciences has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Do institutionals and insiders believe in DNTH or TLSA? 47.5% of Dianthus Therapeutics shares are owned by institutional investors. 16.6% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 39.8% of Tiziana Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Is DNTH or TLSA more profitable? Tiziana Life Sciences has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -1,250.32%. Tiziana Life Sciences' return on equity of 0.00% beat Dianthus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dianthus Therapeutics-1,250.32% -21.68% -20.88% Tiziana Life Sciences N/A N/A N/A SummaryDianthus Therapeutics and Tiziana Life Sciences tied by winning 8 of the 16 factors compared between the two stocks. Remove Ads Get Tiziana Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TLSA vs. The Competition Export to ExcelMetricTiziana Life SciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$129.64M$6.99B$5.68B$8.30BDividend YieldN/A2.72%4.55%4.02%P/E RatioN/A7.2324.5519.25Price / SalesN/A230.77395.7294.10Price / CashN/A65.6738.1634.64Price / Book24.606.617.064.46Net Income-$17.69M$142.13M$3.19B$247.07M7 Day Performance-11.19%1.72%0.18%1.77%1 Month Performance25.51%2.31%5.53%-3.31%1 Year Performance189.21%-5.07%14.21%5.26% Tiziana Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TLSATiziana Life Sciences0.5389 of 5 stars$1.23+13.9%N/A+171.5%$129.64MN/A0.008Gap DownDNTHDianthus Therapeutics1.3268 of 5 stars$21.97+3.0%$52.14+137.3%-41.0%$650.25M$6.24M-8.7980High Trading VolumeLENZLENZ Therapeutics2.1712 of 5 stars$23.59-7.3%$35.40+50.1%+61.9%$648.75MN/A0.00110Earnings ReportAnalyst RevisionCRMDCorMedix2.0388 of 5 stars$10.47flat$16.00+52.8%+79.9%$635.29M$12.26M-12.9330Earnings ReportAnalyst ForecastOptions VolumeNews CoverageGap DownSIONSionna TherapeuticsN/A$14.89-0.6%$38.50+158.6%N/A$633.14MN/A0.0035Earnings ReportORGOOrganogenesis3.1113 of 5 stars$4.97-0.8%$5.50+10.7%+99.2%$630.34M$482.04M-82.83950ABUSArbutus Biopharma2.2125 of 5 stars$3.28-0.6%$5.50+67.7%+35.3%$621.53M$6.74M-7.6390Upcoming EarningsSANASana Biotechnology3.1032 of 5 stars$2.77-5.5%$12.25+342.2%-76.3%$618.46MN/A-1.98380News CoverageCDXCChromaDex4.3939 of 5 stars$7.94+1.3%$9.03+13.8%N/A$617.34M$99.60M794.79120KALVKalVista Pharmaceuticals4.4803 of 5 stars$12.49-0.9%$23.80+90.6%+12.3%$617.23MN/A-3.43100MGTXMeiraGTx4.7042 of 5 stars$7.87+1.0%$24.50+211.3%+21.5%$615.06M$13.93M-6.50300High Trading Volume Remove Ads Related Companies and Tools Related Companies DNTH Competitors LENZ Competitors CRMD Competitors SION Competitors ORGO Competitors ABUS Competitors SANA Competitors CDXC Competitors KALV Competitors MGTX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TLSA) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredThis Crypto Is Set to Explode in FebruaryBryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tiziana Life Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Tiziana Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy TLSA Stock Free TLSA Stock Alerts